The Avandia (rosiglitazone) debate will heat up again now that FDA will loosen its restrictions

January 2014

The Avandia (rosiglitazone) debate will heat up again now that FDA will loosen its restrictions.

This decision is based on a reanalysis of the RECORD trial that suggests Avandia DOES NOT increase cardiovascular risk.

But experts warn that reanalyzing a flawed study doesn't make it valid...and other studies DO suggest Avandia increases CV risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote